CGEM vs MRK
CGEM: Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases. MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
Side-by-side fundamentals
| Metric | CGEM | MRK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.65 | $127.47 | |
| Market cap as of 2026-07-23 | $1.1B | $315.3B | |
| P/E as of 2026-07-23 | n/a | 35.29 | |
| PEG as of 2026-07-23 | -0.24 | 4.34 | CGEM lower |
| Net margin as of 2026-07-23 | -346.2% | +13.6% | MRK higher |
| Gross margin as of 2026-07-23 | n/a | +78.1% | |
| Operating margin as of 2026-07-23 | -358.8% | +18.2% | MRK higher |
| ROE as of 2026-07-23 | -51.4% | +17.9% | MRK higher |
| ROA as of 2026-07-23 | -47.6% | +7.0% | MRK higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.07 | CGEM lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +2.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +3.1% | |
| Dividend yield as of 2026-07-23 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.00 | 0.21 | |
| 1-year return as of 2026-07-22 close | +140.2% | +56.2% | CGEM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.